DXCM Stock Recent News
DXCM LATEST HEADLINES
BNN Bloomberg reported in July 2023 that the S&P 500 was overvalued by about 8%, according to Cresset Capital Chief Information Officer Jack Ablin. In the eight months since, it's up another 19%, providing plenty of overvalued S&P 500 stocks to avoid.
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors are optimistic about DexCom's (DXCM) strong product portfolio.
Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
Zacks.com users have recently been watching DexCom (DXCM) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
DexCom (DXCM) closed at $134.17 in the latest trading session, marking a -0.41% move from the prior day.
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
The latest trading day saw DexCom (DXCM) settling at $133.04, representing a -1.63% change from its previous close.